Opportunities in the pharmaceutical industry include innovation in biologics, growth in GLP-1 therapies and precision oncology, rising demand for advanced treatments, and expanding manufacturing in ...

The Danish drugmaker becomes the latest major pharmaceutical company to embed AI across its entire drug development pipeline, ...

West Pharmaceutical Services, Inc. WST is well-positioned for growth, backed by strong demand for HVPs, expanding GLP-1 drug ...

Non-GLP-1 obesity drugs are emerging in the market, with this landscape expected to surge 50-fold, generating $15.5bn in 2031.

The Indian domestic pharmaceutical market grew to ₹2.46 lakh crore in FY26, fueled by a 13.6% jump in the cardiac segment and ...

Two days after offering compounded versions of oral Wegovy, telehealth company Hims & Hers pulled the product from its platform amid pressure from HHS and Novo Nordisk. On Feb. 5, Hims & Hers began ...

West Pharmaceutical Services earns a Buy rating with a $320 price target, reflecting ~18% upside with strong long-term growth prospects. WST's high-value product mix is expanding, driving margin ...

As GLP-1 weight-loss drugs have moved from a niche treatment to a mainstream prescription, their impact has started showing up well beyond pharmacies. They've quietly reconfigured supply chains, ...

A majority of people who start the obesity and diabetes medicines known as GLP-1s also quit them, and plan to restart again.